Former Chief Commercial Officer (5) · Axsome Therapeutics, Inc. (AXSM)

David Marek

A named executive officer of Axsome Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$2,455,147

Salary $385,000Stock awards $392,387

FY2019: $2,969,931

2nd of 4 named executive officers at Axsome Therapeutics by FY2020 total.

4 named officers on file for Axsome Therapeutics, FY2020

David Marek’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • AXSM’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Axsome Therapeutics’s whole pay program stands against its peers

  • Axsome Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AXSM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 23, 2021 (DEF 14A).

Free

Get David Marek’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

David Marek compensation by year

Axsome Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Axsome Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020
Salary$128,333$385,000
Bonus$65,000$0
Stock awards$0$392,387
Option awards$2,545,597$1,133,385
Non-equity incentive$231,000$0
Pension and deferred compensation$0—
All other$0$544,375
Total$2,969,931$2,455,147

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Axsome Therapeutics, Inc. DEF 14A filed April 23, 2021, accession 0001564590-21-020383, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Axsome Therapeutics, Inc. filed document, accession 0001564590-21-020383. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2021.

$3.0M
$2.5M
FY19
FY20
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU12,544$1,022,774—
Option85,937—$24.28
Option9,678—$17.61
Option30,881—$45.14

Per the Outstanding Equity Awards at Fiscal Year-End table in Axsome Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Axsome Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Herriot TabuteauChief Executive Officer, President and Chairman of the Board$7,304,690
David Marek · this pageFormer Chief Commercial Officer (5)$2,455,147
Mark JacobsonChief Operating Officer$2,365,005
Nick PizzieChief Financial Officer$2,365,005

The full Axsome Therapeutics compensation record

free company brief

This page is one person within Axsome Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Axsome Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Marek's compensation dossier · One-time report. No refunds.